Previous Article | Next Article 
Journal of Virology, October 2000, p. 9668-9679, Vol. 74, No. 20
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Comparison of Second-Strand Transfer Requirements
and RNase H Cleavages Catalyzed by Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) and E478Q RT
Christine Smith
Snyder and
Monica J.
Roth*
Department of Biochemistry, University of
Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical
School, Piscataway, New Jersey 08854
Received 1 March 2000/Accepted 7 July 2000
 |
ABSTRACT |
Truncated tRNA-DNA mimics were examined in an in vitro assay for
second-strand transfer during human immunodeficiency virus type 1 (HIV-1) reverse transcription. Strand transfer in this system requires
the progressive degradation of the RNA within the 18-mer tRNA-DNA
(plus-strand strong stop DNA) intermediate to products approximately 8 nucleotides in length. The ability of the truncated substrates to
substitute for directional processing by RNase H or reverse
transcriptase (RT) was examined. Using wild-type HIV-1 RT, substrates
which truncated the 5' end of the tRNA primer by 6, 9, and 12 nucleotides (
6,
9, and
12, respectively) were recognized by
RNase H and resulted in strand transfer. An overlap of 5 nucleotides
between the acceptor and newly synthesized DNA template was sufficient
for strand transfer. The mutant RT, E478Q correctly catalyzed the
initial cleavage of the 18-mer tRNA-DNA mimic in the presence of
Mn2+; however, no directional processing was observed. In
contrast, no RNase H activity was observed with the
6,
9, and
12 substrates with E478Q RT in this strand transfer assay. However,
when complemented with Escherichia coli RNase H, E478Q RT
supported strand transfer with the truncated substrates. E478Q RT did
cleave the truncated forms of the substrates,
6,
9, and
12, in
a polymerase-independent assay. The size requirements of the substrates
which were cleaved by the polymerase-independent RNase H activity of
E478Q RT are defined.
 |
INTRODUCTION |
Reverse transcription is a multistep
process that is carried out by one virus-encoded enzyme, reverse
transcriptase (RT). RT is a multifunctional enzyme which possesses
RNA-dependent and DNA-dependent polymerase activities and RNase H
activity. RNase H functions to remove RNA when it is present in an
RNA-DNA hybrid (for a review, see reference 2).
In the process of reverse transcription, the viral RNA is converted to
double-stranded DNA, which is subsequently integrated into the host
genome. Human immunodeficiency virus type 1 (HIV-1) reverse
transcription is initiated (3, 25-27, 33) using the cellular tRNALys,3 as a primer (28, 35, 36). The
first 18 3' nucleotides of the tRNA primer are complementary to the
primer binding site (PBS) sequence on the viral genome. Elongation of
minus-strand synthesis pauses at the 5' terminus of the viral RNA
(31), completion of which requires a strand transfer,
referred to as minus-strand or first-strand transfer. Plus-strand
synthesis is initiated at the polypurine tract and continues through
cDNA synthesis of the first 18 nucleotides of the tRNA primer (2,
4, 7). The second-strand transfer requires removal of the tRNA
primer (4, 46, 50, 58), which allows an acceptor PBS
molecule to enter, and subsequent completion of viral DNA synthesis.
HIV-1 RT consists of a heterodimer of two subunits, p66 and p51
(14, 34). The p66 subunit consists of the polymerase and the
RNase H domains; the p51 subunit lacks the RNase H domain. Based on
resemblance of the crystal structure to a right hand (1,
30), the subunits have been further divided into subdomains: palm, finger, thumb, connection, and RNase H. Mutagenesis studies have
identified interactions between the polymerase and RNase H domains.
Mutations within the thumb subdomain and the primer grip and deletions
in the p51 C terminus decrease RNase H activity (9, 18, 21,
44).
During the viral life cycle, RNase H functions to degrade the viral
genome, generate and remove the polypurine tract primer, and remove the
tRNA primer. Removal of the tRNA primer has been extensively
characterized for HIV-1 RT, Moloney murine leukemia virus RT, and an
isolated HIV-1 RNase H domain (48, 49, 59). RNase H activity
has been classified as either polymerase dependent or polymerase
independent (2). The polymerization active site is spatially
separated from the RNase H active site; polymerase-dependent RNase H
activity results in RNase H cleavages which lag approximately 18 to 20 nucleotides behind the site of polymerization (55, 56). The
catalytic residues of the RNase H active site are Asp 443, Glu 478, and
Asp 498 (13, 17, 47). The requirements of RNase H activity
during HIV-1 reverse transcription have been further characterized
through the analysis of an RNase H-defective mutant, E478Q RT. This
RNase H mutant possesses only Mn2+-dependent RNase H
activity. Additionally, it is capable of only a single
endoribonucleolytic cleavage and lacks the ability to further degrade
the tRNA primer (10).
Previously, we showed that RNase H activity is required for the HIV-1
second-strand transfer (50). More specifically, a single
endoribonucleolytic cleavage is not sufficient to allow release of the
tRNA primer. Rather, subsequent RNase H degradation must be carried out
by RT or through complementation with Escherichia coli RNase
H. We have now investigated the ability of HIV-1 RT and a mutant
enzyme, E478Q RT, to support strand transfer with substrates possessing
truncations in the 5' portion of the tRNA primer. These substrates have
the potential to substitute for RNase H-catalyzed directional
processing, due to their decreased melting temperatures
(Tm). If properly cleaved by E478Q RT, the truncated substrates could potentially support strand transfer without
complementation by E. coli RNase H. In
polymerase-independent assays, the truncated substrates were recognized
and cleaved by E478Q RT. However, the results indicate a differential
recognition by wild-type (WT) RT and E478Q RT on the truncated
substrates in second-strand transfer reactions. Utilizing an in vitro
strand transfer assay, we have shown that 5 nucleotides of overlap
between the newly synthesized DNA strand and the acceptor molecule is sufficient for strand transfer.
 |
MATERIALS AND METHODS |
Enzymes and nucleotides.
[
-32P]ATP was
purchased from ICN. T4 polynucleotide kinase was purchased from New
England Biolabs. RNasin was purchased from Promega. Klenow Exonuclease
(
) was purchased from Boehringer Mannheim. HIV-1 RT was obtained
either from Jeffrey Culp and Christine Debouch, Department of Protein
Biochemistry, SmithKline Beecham Pharmaceuticals (37), or
from Stuart Le Grice. The two HIV-1 RT preparations displayed
equivalent specificity in the tRNA removal assay, indicating that
variations in the expression and purification schemes did not result in
altered biochemical properties (data not shown). The presence of the
histidine tag on the HIV-1 RT has been previously shown not to
influence catalytic functions (32). HIV-1 RT E478Q mutant
was obtained from Stuart F. Le Grice and the AIDS repository
(contributor, Stuart F. Le Grice). HIV-1-isolated RNase H (NY427) was
purified from E. coli containing plasmid pET-NY427 (52). E. coli RNase H was purchased from Gibco BRL.
Oligonucleotides.
The RNA-DNA hybrid oligonucleotides (RNA
is indicated in bold) 17-mer (5' GUUCGGGCGCCACTGCT
3'), 14-mer (5' CGGGCGCCACTGCT 3'), 11-mer
(5' GCGCCACTGCT 3'), 17-mer (DNA) (5'
AGCAGTGGCGCCCGAAC 3'), 14-mer (DNA) (5' AGCAGTGGCGCCCG
3'), 11-mer (DNA) (5' AGCAGTGGCGC 3'), HTD-1 (5'
GTGTGGAAAATCTCTAGCAGTGGCGCCCCGAACAGGGA 3'), 17080 (5'
ATCTCTAGCAGTGGCGCCCGAACAGGGAC 3'), and 17081 (5'
GAAAATCTCTAGCAGTGGCGCCCGAACAGGGAC 3') were synthesized by
Integrated DNA technologies. Oligonucleotides 5785 (5'
CCCTCAGCCCTTTTAGTCAGTGTGG 3'), 5786 (5'
CCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGCGA 3'), 5331 (5' AGCAGTGGCGCCCGAACGCGGGGCTTGTCCCT 3'),
and 5580 (5' TTTCGCTTTCAGGTCCCTGTTCGGGCGCCA 3') were
synthesized by the University of Medicine and Dentistry of New Jersey.
Strand transfer substrate preparation.
The truncated RNA-DNA
hybrid strand transfer substrates were prepared as follows. Portions
(20 pmol) of the 17-mer, 14-mer, and 11-mer RNA-DNA hybrids were 5'-end
labeled using T4 polynucleotide kinase and [
-32P]ATP.
The radiolabeled RNA-DNA oligonucleotides were isolated utilizing G-25
spin columns (Boehringer Mannheim). The labeled substrates were
annealed to 40 pmol of oligonucleotide 5786 in a 25-µl reaction
mixture containing 50 mM Tris-HCl (pH 8.0), 50 mM KCl, 8 mM
MgCl2, and 2 mM dithiothreitol (DTT). The substrates were
extended using Exonuclease (
) Klenow, isolated on gels, and eluted
overnight as previously described (50). The product sizes
for the input 17-mer, 14-mer, and 11-mer RNA-DNA hybrids are 44-mer,
41-mer, and 38-mer, respectively. The substrates were then annealed to
oligonucleotide 5785 (referred to as 26-mer). This oligonucleotide was
also 5'-end labeled in the same manner as described for the RNA-DNA hybrids.
Strand transfer reactions.
Reactions were performed as
previously described (50). Briefly, the annealed RNA-DNA
hybrid substrates were incubated with either HIV-1 RT or E478Q RT. The
strand transfer reactions were performed in a 20-µl reaction mixture
containing approximately 4 pmol of substrate (substrate refers to the
50-mer RNA-DNA oligonucleotide annealed to primer 5785), 4 pmol of
acceptor (oligonucleotide 5580), and 2 pmol of either HIV-1 RT or E478Q
RT in a reaction buffer containing 20 mM Tris-HCl (pH 7.5), 50 mM KCl,
8 mM MgCl2 or 8 mM MnCl2, 2 mM DTT, and 0.25 µM each deoxynucleoside triphosphate (dNTP) (dATP, dCTP, dGTP, and
TTP). Reactions were initiated upon the addition of enzyme and
performed at 37°C. Aliquots (2.5 µl) were removed at the indicated
time points. The reaction products were analyzed on a 15%
polyacrylamide denaturing gel and exposed to autoradiography film.
In reactions in which multiple enzymes were used, such as E. coli RNase H, 1 pmol of the additional enzyme was added after the
12-min time point.
RNase H cleavage assays.
Reactions were performed as
previously described (49). Briefly, approximately 4 pmol of
the indicated RNA-DNA hybrid substrate was incubated with either 1 pmol
of HIV-1 RT or E478Q RT. RNase H cleavage substrates were prepared in
the same manner as described for the strand transfer substrates. The
annealing templates used for extension templates were oligonucleotides
5786, HTD-1, 17081, 17080, and 5531 for substrates B to F (see Fig. 6),
respectively. These newly extended substrates were gel isolated and
eluted as previously described (50). The substrates were
again annealed to their corresponding extension templates. The reaction
mixture (20 µl) contained 20 mM Tris-HCl (pH 7.5), 50 mM KCl, 8 mM
MnCl2, and 2 mM DTT. Time course reactions were performed,
and 3-µl aliquots were removed at 0, 2, 5, 15, and 30 min. Samples
were analyzed on a 20% polyacrylamide denaturing gel and exposed to
autoradiography film.
 |
RESULTS |
Strand transfer assays with truncated substrates.
The
second-strand transfer is a vital intermediary step in the synthesis of
full-length double-stranded retroviral DNA. An in vitro assay has been
developed to analyze the second-strand transfer reaction during HIV-1
reverse transcription (50). In this assay, model substrates
were constructed which mimic the intermediate formed during plus-strand
strong stop synthesis in which the first 18 nucleotides of the tRNA
primer are reverse transcribed (Fig. 1,
step 2). In the removal of the tRNA, the initial cleavage occurs at the
penultimate nucleotide at the 3' end of the tRNA (step 3) (51,
53). Previous studies have indicated that the tRNA needs to
undergo further degradation for strand-transfer to proceed
(50). Once the tRNA is removed, the acceptor molecule can
enter and a 70-mer strand transfer product results (step 4).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 1.
Second-strand transfer assay with model substrates. This
illustrates the model strand transfer assay with the truncated
substrate possessing only 12 ( 6), 9 ( 9), and 6 ( 12) positions
of the RNA sequence. Step 1 illustrates the input substrate for each
truncated substrate, along with their respective input RNA-DNA sizes.
Step 2 illustrates the polymerization reaction which can occur in the
presence of RT and dNTPs and the size of the polymerization product for
each substrate, 52-mer ( 6), 49-mer ( 9), and 46-mer ( 12). DNA
polymerization creates the RNA-DNA hybrid, which is a substrate for the
RNase H domain (step 3). Once the RNA has been removed between the
terminal ribo-A and ribo-C, the acceptor molecule can enter and produce
a strand transfer product, 70-mer (step 4). In each step, the RNA
portion is indicated in bold and the 5' radiolabel is indicated by an
asterisk. The size of the strand transfer product (70-mer) would be the
same for each truncated substrate.
|
|
Previous analysis indicated the RNase H-defective mutant, E478Q RT, was
capable of performing only a single endoribonucleolytic
cleavage in
removing the tRNA primer (
10,
50). Using our model
system,
this cleavage yields a 17-mer RNase H cleavage product,
which was not
sufficient for strand transfer to proceed (
50).
Therefore,
it was reasoned that decreasing the size of the RNA
component would
lower the
Tm of the RNA-DNA hybrid and could
compensate
for the lack of directional processing by E478Q RT. Model
substrates
were constructed that truncated the 5' terminus of the RNA
by
6, 9, or 12 nucleotides and were named

6,

9, and

12,
respectively
(Fig.
1). These truncated substrates were specifically
recognized
and cleaved at the expected position by both WT HIV-1 RT and
an
isolated HIV-1 RNase H domain (
49).
Figure
1 summarizes the second-strand transfer assay with substrates
possessing truncations in the 5' RNA portion. Step 1
represents the
input substrates for the

6,

9, and

12 constructs,
in which the
RNA-DNA oligonucleotides are hybridized with plus-strand
primer 5785. In the presence of dNTPs and WT HIV-1 RT, polymerization
occurs (step
2) and the full-length plus-strand product is synthesized.
In this
complex, the RT is paused with the terminus of the nucleic
acid
substrate bound in the polymerase active site. Once the RNA-DNA
hybrid
is formed, RNase H can cleave the RNA primer (step 3).
Using a
full-length 18-mer RNA, at the completion of plus-strand
synthesis, the
E478Q RNase H active site is optimally positioned
for the single
endoribonucleolytic cleavage to occur through a
polymerase-dependent
mechanism. However, with the truncated substrates,
a
polymerase-independent RNase H cleavage would be required to
remove the
RNA, since in a polymerase-dependent assay, the RNase
H active site
would be positioned within a double-stranded DNA
region. Once the RNA
primer is removed, the acceptor molecule
enters and a 70-mer strand
transfer product is produced (step
4). Decreasing the size of the RNA
template affects the overlap
between the newly synthesized DNA strand
and the acceptor molecule.
As the truncation increases, the amount of
overlap between the
acceptor and newly synthesized strand decreases.
This assay therefore
allows the determination of the minimum overlap
sequence required
for strand transfer to
occur.
HIV-1 RT assayed with truncated substrates.
The truncated
substrates (
6,
9, and
12) were assayed with WT HIV-1 RT (Fig.
2) in the presence of Mg2+,
dNTPs, and acceptor molecule. Reactions performed in the presence of
Mn2+ yielded equivalent results (data not shown). Figure 2
represents time courses from 0 to 30 min. Lanes 1 to 6 represent HIV-1
strand transfer reactions with the
6 construct. The plus-strand
oligonucleotide, 5785, was quickly extended from a 26-mer to the 52-mer
product. The RNA portion of the RNA-DNA hybrid was degraded by the
RNase H domain, and a strand transfer product (70-mer) was produced. Similarly, HIV-1 RT was capable of polymerization, RNase H activity, and strand transfer on the
9 substrate (lanes 7 to 12). The
12 construct was also assayed with HIV-1 RT (lanes 13 to 18). This construct had the largest deletion, possessing only 6 nucleotides of
the tRNA primer. Therefore, there was only 5 bp of overlap between the
acceptor and the newly synthesized DNA strand to support strand
transfer. This substrate also successfully produced a strand transfer
product (70-mer), albeit at lower efficiency. This result indicated
that a 5-nucleotide overlap between the newly synthesized DNA strand
and the acceptor strand is sufficient to support strand transfer.

View larger version (102K):
[in this window]
[in a new window]
|
FIG. 2.
Truncated substrates assayed with HIV-1 RT. Reactions
were performed as described in Materials and Methods. Lanes 1 to 6, 7 to 12, and 13 to 18 represent HIV-1 RT incubated with the 6, 9,
and 12 constructs, respectively. Time points are indicated above
each lane in minutes. Strand transfer products (70-mer), DNA primer
(26-mer), and RNase H products are indicated by arrows. Input
substrates for the 6, 9, and 12 constructs are 44-mer, 41-mer,
and 38-mer, respectively. Initial RNase H cleavage products for the
6, 9, and 12 constructs are 11-mer, 8-mer, and 5-mer,
respectively.
|
|
E478Q RT assayed with the truncated substrates.
The truncation
substrates were assayed with E478Q RT in the same manner as for HIV-1
RT, except that reactions were performed in the presence of
Mn2+. Previous analysis indicated that the addition of
Mn2+ to the WT HIV-1 RT does not change the RNase H or
strand transfer properties of the enzyme, allowing direct comparison of
the WT and E478Q mutant RT (50). It had been postulated that
the single E478Q RNase H cleavage on the
9 and
12 substrates
would release 8-mer and 5-mer RNA species, respectively. The reaction
temperature is above the Tm of the products and
would allow dissociation of the RNA. The Tm of
the
6 construct, at approximately 42°C, may be too high for
dissociation to occur. In previous studies, strand transfer correlated
with the appearance of 8-mer RNA products (42, 50). Figure
3, lanes 1 to 6, lanes 7 to 12, and lanes 13 to 18 represent E478Q RT assayed with the truncations
6,
9, and
12 respectively. For all of the constructs, extension products were observed, indicative of complete synthesis. Interestingly, no
RNase H cleavage products were observed for any of the constructs assayed in the presence of E478Q RT. Reactions performed for up to 40 min and/or in the presence of both divalent cations did not yield RNase
H cleavage products (data not shown). A band was observed with the
6
construct (lanes 2 to 6). However, this band was also present in the
absence of enzyme (lane 1) and is therefore not an RNase H cleavage
product. These results were surprising because previously, E478Q RT was
capable of producing an RNase H cleavage product on the intact
full-length substrate (50). Without any RNase H activity,
E478Q RT was unable to proceed with strand transfer. It was therefore
possible that E478Q RT was not capable of catalyzing the
polymerase-independent RNase H cleavages required for strand transfer
in this modified assay.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 3.
Truncated substrates assayed with E478Q RT. Reactions
were performed as described in Materials and Methods. Lanes 1 to 6, 7 to 12, and 13 to 18 represent E478Q RT assayed with the 6, 9, and
12 constructs, respectively. Time points are indicated above each
lane in minutes. Strand transfer products (70-mer), DNA primer
(26-mer), and RNase H products are indicated by arrows. Input
substrates for the 6, 9, and 12 constructs are 44-mer, 41-mer,
and 38-mer, respectively. Initial RNase H cleavage products for the
6, 9, and 12 constructs are 11-mer, 8-mer, and 5-mer,
respectively.
|
|
Complementation of HIV-1 RT and E478Q RT with E. coli
RNase H.
To further characterize the defects of E478Q RT with
regard to its RNase H cleavage, it was necessary to determine that this mutated enzyme could perform strand transfer under these modified conditions with the truncated substrates. Therefore, both HIV-1 RT and
E478Q RT were complemented with E. coli RNase H in a strand transfer reaction. The reactions were performed in the presence of
Mg2+, dNTPs, and acceptor; E. coli RNase H was
added after the 12-min time point for both enzymes. Under these
conditions, both the WT HIV-1 RT and E. coli RNase H were
active and their products could be distinguished. The WT HIV-1 RT
products (Fig. 4A, lanes 3, 9, and 15)
were similar to those identified in Fig. 2 (lanes 3, 9, and 15).
Addition of E. coli RNase H after 12 min resulted in much
more extensive RNase H degradation (Fig. 4, lanes 4, 10, and 16, indicated by vertical arrows). For E478Q RT, the visible cleavage
activity can only be a result of E. coli RNase H since the
reactions were performed in Mg2+ alone. The results of time
course analyses using HIV-1 RT and E478Q RT are shown in Fig. 4A and B,
respectively. Complementation of HIV-1 RT with E. coli RNase
H was similar to the results (lanes 1 to 6, lanes 7 to 12, and lanes 13 to 18) with HIV-1 RT alone. A 70-mer strand transfer product was
produced in each case. With HIV-1 RT, only a single RNase H cleavage
product was observed for the
12 construct (Fig. 2). However,
addition of E. coli RNase H yielded RNA products as small as
a diribonucleotide (Fig. 4A, lane 16).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 4.
(A) Complementation of HIV-1 RT with E. coli
RNase H. Reactions were performed as described in Materials and
Methods. Input RNA-DNA, DNA primer, and RNase H cleavage products are
indicated by arrows. Reactions were allowed to proceed for 12 min in
the presence of Mg2+, and then of E. coli RNase
H was added (indicated by the vertical arrows). Time points are
indicated above each lane in minutes. (B) Complementation of E478Q RT
with E. coli RNase H. Reactions were performed as described
for panel A. Time points are indicated above each lane in minutes.
Input RNA-DNA, DNA primer, and RNase H cleavage products are indicated
by arrows.
|
|
Complementation of E478Q RT with
E. coli RNase H on the

6,

9, and

12 substrates (Fig.
4B, lanes 1 to 6, lanes 7 to 12,
and lanes 13 to 18, respectively) did indeed result in the 70-mer
strand transfer product. These results confirmed the requirement
of
RNase H activity for strand transfer to take place. These experiments
also reinforce the finding with HIV-1 RT that the 5-base overlap
between donor and acceptor was sufficient for strand transfer
to
proceed.
E478Q RT in a polymerase-independent assay.
Previous
characterization of E478Q indicated that it lacks directional RNase H
processing (10) during polymerization. However, the question
remained whether E478Q RT can perform any polymerase-independent RNase
H cleavages. To test this, a series of short, truncated substrates were
generated (Fig. 5A). If RNase H cleavage
occurred at the initial (
1) position (indicated by the arrow)
(51, 53), substrate binding could not be dictated by the
positioning of the 3'OH in the polymerase active site. These RNA
substrates contained the same 5'-terminal truncations as the RNAs in
the strand transfer assay. Additionally, these substrates truncated the
DNA in the RNA-DNA oligonucleotide to 5 nucleotides (Fig. 5A). The
RNA-DNA strands were hybridized to DNA oligonucleotides 17, 14, and 11 nucleotides in length, yielding blunt-ended substrates.

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 5.
E478Q RT assayed in polymerase-independent assay. (A)
The substrates utilized are illustrated. Substrates were labeled at the
5' termini with [ -32P]ATP and prepared as described in
Materials and Methods. An asterisk indicates the radiolabel. The RNA
portion is indicated in bold. (B) HIV-1 RT assayed with 17-mer (lanes 1 to 5), 14-mer (lanes 6 to 10), 11-mer (lanes 11 to 15); E478Q RT
assayed with 17-mer (lanes 16 to 20), 14-mer (lanes 21 to 25), and
11-mer (lanes 26 to 30). Time points are 0, 2, 5, 15, and 30 min for
each set of lanes. Reactions were performed as described in Materials
and Methods.
|
|
Figure
5B illustrates these substrates assayed with HIV-1 RT or E478Q
RT. Figure
5B, lanes 1 to 5, 6 to 10, and 11 to 15 represent
HIV-1 RT
assayed with the truncated substrates. For the 17-mer
(lanes 1 to 5),
14-mer (lanes 6 to 10), and 11-mer (lanes 11 to
15) substrates, the
correct cleavage products at the

1 position
were observed, as
indicated by the arrows. These cleavage events
have been extensively
characterized for HIV-1 RT and an isolated
HIV-1 RNase H domain with a
related substrate containing a complementary
oligonucleotide carrying
the entire 18-nucleotide PBS sequence
(
49). The 17-mer,
14-mer, and 11-mer substrates assayed with
E478Q RT are shown in Fig.
5B, lanes 16 to 20, 21 to 25, and 26
to 30, respectively. E478Q RT was
capable of cleaving the 17-mer
and 14-mer constructs at the predicted

1 position. In contrast
to WT RT, E478Q RT did not cleave the 11-mer
construct. These
results indicate that on defined substrates, E478Q RT
is capable
of polymerase-independent
cleavages.
RNase H cleavage analysis of the truncated DNA substrates.
E478Q RT-RNase H recognized and cleaved the blunt 17-mer and 14-mer
RNA-DNA hybrid substrates (Fig. 5B) but was inactive on the equivalent
52-mer (
6) and 49-mer (
9), RNA-DNA hybrid resulting after
polymerization (Fig. 3). Two key differences between these substrates
are the size of the DNA-DNA hybrid segment and the position of a 3'OH
group with respect to the RNA-DNA hybrid. A large DNA substrate may
lock the 3'OH within the polymerase active site, whereas a small
substrate may have sufficient flexibility to permit binding of the
substrate into the RNase H active site.
To address this, a series of substrates were constructed which varied
the length of the double-stranded (ds) U5 DNA associated
with the
tRNA-DNA mimic (Fig.
6A).
The sizes of the ds DNAs ranged
from
those that were cleaved, (17-mer; 5-mer DNA plus 12-mer RNA)
to those
not recognized by E478Q (substrate B; 32-mer DNA plus
12-mer RNA).
E478Q RT was capable of recognizing and cleaving
a 50-mer
RNA-DNA hybrid substrate containing the intact 18-mer
RNA portion plus a 32-mer of DNA (substrate A). However, when
the RNA
portion of the substrate was truncated by 6 nucleotides
(substrate B),
RNase H cleavage was inhibited. Substrates were
constructed in which
the DNA-DNA (ds DNA portion) size varied
but the size of the RNA-DNA
hybrid remained constant (12-mer RNA).
Substrates C, D, E, and F
possessed 20, 14, 11, and 7 nucleotides,
respectively, of ds DNA. The
17-mer (5-mer DNA plus 12-mer RNA)
and 14-mer substrates (5-mer DNA
plus 9-mer RNA) were shown to
be cleaved by E478Q RT (see above) (Fig.
5B).


View larger version (120K):
[in this window]
[in a new window]
|
FIG. 6.
RNase H cleavage analysis of truncated DNA substrates.
(A) The substrates utilized are illustrated and are labeled A through
F. The RNA portions are indicated in bold, and an asterisk indicates
the radiolabel. The substrates were prepared as described in Materials
and Methods. (B) Substrates B to F assayed with HIV-1 RT. Reactions
were performed as described in Materials and Methods. Time course
reactions are shown, and time points are indicated above each lane,
along with the substrate utilized. The RNase H cleavage product is
designated and indicated by an arrow. (C) Substrates B to F assayed
with E478Q RT. Reactions were performed as described in Materials and
Methods. Time course reactions are shown, and time points are indicated
above each lane, along with the substrate utilized. The RNase H
cleavage product is designated and indicated by an arrow.
|
|
HIV-1 RT and E478Q RT were assayed for their abilities to cleave these
substrates in a polymerase-independent assay (Fig.
6B and C,
respectively). For HIV-1 RT, all of the newly constructed
substrates
(substrates B to F) were cleaved, indicating that the
substrates were
intact RNA-DNA hybrids (Fig.
6B). Since all of
the substrates contained
12 nucleotides of RNA, the RNase H cleavage
sites were identical and an
11-mer RNA cleavage product was observed
for each substrate. In
contrast, with E478Q RT (Fig.
6C), the
only substrate that was
efficiently cleaved was substrate F, which
possessed 7 nucleotides in
the DNA-DNA portion and 12 nucleotides
in the RNA-DNA hybrid portion of
the substrate. The total size
of this substrate was 19-mer (7-mer DNA
plus 12-mer RNA), which
approached that required for
polymerase-dependent RNase H cleavages.
This was only 2 nucleotides
larger than the 17-mer substrate previously
cleaved by E478Q RT (Fig.
5B). This result indicates that E478Q
RT can perform
polymerase-independent RNase H cleavages only on
defined small
substrates. It is of interest that these substrates
are equal to or
less than the length defined between the polymerase
and RNase H active
sites.
 |
DISCUSSION |
Two different modes of RNase H activity have been characterized
for HIV-1 RT: polymerase dependent and polymerase independent (20). Polymerase-dependent RNase H cleavages are those that occur while the polymerase domain is actively synthesizing. The RNase H
active site lags approximately 18 to 20 nucleotides behind the
polymerase active site, which has been characterized through footprinting analysis for HIV-1 RT and Moloney murine leukemia virus RT
(55, 57). On the plus-strand strong stop tRNA-DNA, tRNA
removal occurs while the RT is paused trying to use the modified tRNA
residue as template. Although the polymerase is not actively synthesizing, the initial RNase H cleavage can be viewed as polymerase dependent since the nucleic acid substrate remains bound in the polymerase active site. The initial RNase H cleavage occurs at the
penultimate nucleotide of the tRNA (53).
Polymerase-independent cleavages are less well understood and may
represent different types of cleavages. These cleavages result in the
production of smaller products (22) and have been defined as
"directional processing of the RNA primer" (10).
Although secondary to the initial cleavage during reverse
transcription, these events are required for the ultimate release of
the RNA primer. Mutants with defects in the ability to perform this
function are unable to perform strand transfer (10, 21, 23,
50). Polymerase-independent RNase H cleavages require a second
binding event by RT (23). This "rebinding" event may
require a change between the type of conformation required for active
DNA synthesis and polymerase-dependent RNase H activity.
We have developed an in vitro assay which requires
polymerase-independent RNase H activity during the second-strand
transfer reaction. Previously, we utilized substrates which mimic the
U5/PBS border, resulting from plus-strand strong stop DNA synthesis. The original substrates possessed either an 18-mer RNA oligonucleotide or the intact tRNALys,3 (50). With those
substrates, the RNase H activity we observed was most probably a
combination of polymerase-dependent and -independent cleavages. The
substrates utilized in this study have truncations in the 5' RNA
portion and have a maximum length of 12 ribonucleotides. Therefore,
cleavage of these substrates would require polymerase-independent RNase H activity, due to the suboptimal distance between the polymerase and RNase H active sites.
A model illustrating the possible binding conformations adopted by WT
RT and E478Q RT is shown in Fig. 7.
This model is based on the crystal
structure of a covalently trapped catalytic complex of RT with DNA
(24) (Fig. 7D, left panel). In this complex, the ds DNA
spans 23 nucleotides and approximates the 12-mer RNA plus 11-mer DNA
substrates used in the present study. In Fig. 7D, left panel, the
substrate is positioned in the polymerase active site (labeled Pol). In
Fig. 7D, right panel, the substrate was modified such that a potential
RNA strand (red) is within the RNase H active site (RH) and extended 12 nucleotides toward the polymerase active site. This substrate lacks the
stabilizing contacts within the thumb domain. The extension of the
substrate exiting the RNase H domain was not modeled due to limited
structural data on these contacts. Figure 7A to C utilize a schematic
of this molecular model to summarize the results presented in this study. On a full-length model substrate (50-mer: 32-mer DNA plus 18-mer
RNA) (Fig. 7A), both E478Q RT and WT HIV-1 RT bind in a polymerase-dependent conformation and produce the well-characterized
1 RNase H cleavage product (depicted as a nick within the RNA [thick
bar]) (50). The size of the RNA portion of the substrate allows correct positioning of the RNase H active site near the RNA-DNA
junction. This RNase H cleavage event is driven by the polymerase
domain and is guided by the 5' phosphate of the RNA and the 3' OH of
the DNA (39).


View larger version (76K):
[in this window]
[in a new window]
|
FIG. 7.
Model of WT RT and E478Q RT polymerase-dependent
and polymerase-independent RNase H activities. The possible binding
orientations for HIV-1 RT and E478Q RT are shown. (A to C) WT RT and
E478Q RT are shown positioned on the various substrates, 50-mer
substrate (32-mer DNA, 18-mer RNA) (A), 44-mer substrate (32-mer DNA,
12-mer RNA) (B), and 19-mer (7-mer DNA, 12-mer RNA) (C). The RNA
portion is indicated by the thick line, and the DNA is indicated by the
solid black line. The position of RNase H cleavage is indicated by a
nick in the RNA strand. The WT and E478Q RT can be distinguished by the
presence of an R (WT) or E/Q (E478Q RT) in the RNase H domain.
Additionally, the thumb and polymerase domains are indicated by T and
P, respectively. The 5' phosphate is indicated, as well as the size of
the RNA on each model substrate. (D) Models of substrates bound in the
polymerase active site (left) and the RNase H active site (right) in
HIV-1 RT. The electrostatic potential mapped on the molecular surface
rendering of the HIV-1 RT (GRASP [38]) is shown with
the template-primer as bound in the structure reported by Huang et al.
(24) (1rtd), and substrates are shown as stick models.
Positively charged amino acids are shown in blue, and negatively
charged amino acids are shown in red. In the right-hand panel, the
substrate found in the 1rtd structure has been truncated to include
only 12 bp of template-primer extending from the RNase H active site.
This truncated substrate makes very limited interactions with the
thumb. T, thumb; F, fingers; RH, RNase H active site; Pol, polymerase
active site.
|
|
Figure 7B represents the truncated substrate (44-mer: 32-mer DNA plus
12-mer RNA). This substrate is suboptimal for a polymerase-dependent mode of binding due to its truncation in the 5' portion of the RNA.
Despite this, the WT RT maintains its RNase H cleavages on these
substrates. This implies that it is capable of the release and
rebinding of these substrates (23). E478Q RT, which is
compromised in the RNase H domain, has regained the single
endoribonucleolytic cleavage ability only in the presence of
Mn2+ (10). E478Q RT binds in the same
polymerase-dependent orientation; however, RNase H cleavage never
occurs because the RNase H active site is never positioned near the
RNA-DNA junction on this substrate. It appears that E478Q in the
presence of Mn2+ has not maintained the ability to
communicate the release and subsequent rebinding to these large
substrates, which possess a larger portion of ds DNA than the smaller
substrates do. Alternatively, catalysis for the polymerase-independent
cleavages may be slower than dissociation on these substrates
(12). In the polymerase-dependent reaction catalyzed by
E478Q, the RNA-DNA hybrid remains accessible to further degradation by
exogenously added E. coli RNase H. This indirectly implies
that the enzyme is released from the substrate. Complementation with
E. coli RNase H is sufficient for subsequent strand transfer
catalyzed by E478Q RT.
When presented with a substrate truncated in the DNA portion as well as
in the RNA portion (19-mer: 7-mer DNA plus 12-mer RNA), E478Q RT was
capable of performing an RNase H cleavage. This substrate (Fig. 7C) is
small enough that it is not locked into the polymerase active site.
Therefore, a polymerase-independent or RNase H active site-driven
cleavage may occur. HIV-1 RT preferentially binds a heteroduplex
RNA-DNA region with a greater affinity than it binds ds DNA
(12), which may be directing the RNase H cleavage. However,
once the DNA portion was increased to 11 nucleotides (23-mer: 11-mer
DNA plus 12-mer RNA), the substrate was again locked into the
polymerase active site and no RNase H activity was observed. This
indicates that the overall substrate size must be smaller than the
distance between the polymerase and RNase H active sites (55,
57) in order for E478Q RT to perform these smaller
polymerase-independent RNase H cleavages. The E478Q mutation may alter
the ability of the enzyme to translocate across larger substrates to
position itself correctly for RNase H cleavage, whereas a smaller
substrate can slide into the RNase H active site.
Several factors have been identified which contribute to the
positioning of the template. These include the position of the primer
3'OH, the position of the 5' phosphate of the RNA, and the minor groove
binding tract within the thumb subdomain. We propose that with
substrates longer than 19 nucleotides, a polymerase-dependent conformation dominates, whereas with the smaller substrates, binding to
either the polymerase or RNase H active sites may occur. This may be a
combination of the high affinity of the polymerase domain for the
termini of the substrate and a result of the defect in the RNase H
domain of E478Q RT. With E478Q, subsequent rebinding to the substrate
may remain driven solely by the recognition of the termini of the
substrate. Rebinding (23) would occur in the same location
and would never position the RNA-DNA substrate in a conformation
required for a polymerase-independent cleavage. It is therefore
surprising that the smaller substrates are capable of binding E478Q
within the RNase H domain. This implies that there may be a stabilizing
effect of having a substrate exit the RNase H domain. Reports have
suggested that substrate binding by the RNase H domain contributes to
processive DNA synthesis (8).
Studies have been performed which show that the 5' end of the RNA
sequence can be responsible for directing its cleavage by HIV-1 RNase H
(39, 40). Those studies suggested that RT is capable of
binding the substrate in two different ways: either based on the 3' end
of the DNA strand or based on the 5' end of the RNA strand. The binding
was dependent on the substrate structure and on whether the DNA or RNA
ends were recessed. When binding was driven by the position of the RNA
5' phosphate, RNase H cleavage still occurred 18 nucleotides upstream,
maintaining the optimal spatial distance between the two active sites.
However, with the substrates utilized in our study, binding of the 5'
phosphate within the polymerase active site would position the RNase H
active site within the ds DNA region. WT RT is able to overcome this obstacle; therefore, this cannot be the dominant feature, since cleavage at the penultimate nucleotide within the RNA was consistently observed.
Another contributing factor may be the role of the p66 thumb subdomain
in positioning the RNA-DNA substrate. In the crystal structure of HIV-1
RT bound with nonnucleoside inhibitor, the position of the thumb
differs from that of the inhibitor free enzyme (11, 15, 16,
45). The
-helix H within the thumb acts as a minor groove
binding tract (5, 6). This helix plays a role in the binding
of primer-template complexes. The RT mutant W266A (mutated within
-helix H) lost the ability to position the 3'OH/5' phosphate within
the polymerase active site and resulted in imprecise removal of the
polypurine tract primer (43). Molecular modeling of a
truncated substrate in the RNase H active site precluded the
interaction of a 12-base extension with the minor groove binding tract
(Fig. 7D, right). Flexibility of the thumb and/or perturbation of the
size of the major and minor groove of the substrate could alter these
interactions. Cooperativity of the thumb with either the polymerase or
RNase H active sites could therefore be a discriminating factor for the
positioning of the tRNA-DNA substrate.
We propose two different binding conformations for HIV-1 RT in removing
the tRNA, a polymerase-dependent binding mode and a
polymerase-independent binding mode. Differential conformations for
endonuclease and exonuclease RNase H activities were previously described (60). Another study demonstrated that in the
switch from initiation to elongation, the RT must dissociate before
efficient and processive elongation can occur (31). That
study also concluded that the length of the synthesized DNA affects
this switch, since it would change the proximity of the RNA/DNA
junction on the primer strand relative to
-helix H. The truncated
substrates utilized in our present study would place the RNase H active
site within the U5 DNA portion once synthesis is complete; therefore,
dissociation would have to occur for any RNase H cleavage to occur.
HIV-1 RT has no defects in its ability to perform this switch and to
cleave truncated substrate intermediates. However, the E478Q RT was
unable to carry out these cleavages on substrates that were identical in size.
The present study has also determined that an overlap of 5 nucleotides
between the acceptor DNA and the newly synthesized plus strand is
sufficient for either the WT RT or E478Q mutant enzyme to perform the
plus-strand transfer. This region of overlap includes the 3'OH of the
primer. Deletions of acceptor molecules which destroy the base pairing
with the primer terminus block plus-strand transfer in vitro and in
vivo (4, 54). Our results are consistent with in vivo
results in which maintenance of 5 nucleotides of the PBS adjacent to U5
plus complementarity of only 3 bp at the site of polymerization was
sufficient for extension of plus-strand DNA during the second template
transfer (54). This result is also in agreement with the
occurrence of retroviral recombination events. In vivo, low levels of
strand transfer events that yield deletions have been characterized
with minimal overlap (41). Studies have shown that there is
an average of 1 aberrant strand transfer event per replication cycle
(29).
Interestingly, WT HIV-1 RT was capable of performing specific RNase H
cleavages on all of the substrates utilized. Truncation of the DNA or
RNA portion did not affect the RNase H cleavage site. Rather, all of
the substrates produced the identical
1 cleavage product. This may be
due to the strong structural recognition of the tRNA mimic or to an
alteration of the binding conformation which allows specific RNase H
cleavages to occur. Previously, we have demonstrated that sequences
within the first nine positions of the tRNA were important for cleavage
and recognition by an isolated RNase H domain (49). These
studies support the concept that the structure defined by the tRNA
sequence possesses strong intrinsic signals that lead to its precise
cleavage between the terminal ribo-A and ribo-C. This cleavage occurs
even when a large portion of the tRNALys,3 sequence has
been deleted.
We have shown that many factors play a role in influencing RNase H
activity. The in vitro system developed allows the biochemical analysis
of a minimal system. In vivo, replication occurs within reverse
transcription complexes (19) in the presence of additional viral proteins, including the nucleocapsid, which can influence these
reactions. The use of an enzyme with defects in the RNase H domain
provides insight into the requirements for polymerase-independent RNase
H cleavages.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH (grants RO1GM51151 and 1RO1 CA90174).
We thank Jeff Culp and Christine DeBouch for the generous gift of HIV-1
RT and Stuart J. F. Le Grice for the gift of E478Q RT and HIV-1
RT. We thank Millie Georgiadis for assistance in molecular modeling.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry, University of Medicine and Dentistry of New
Jersey
Robert Wood Johnson Medical School, Piscataway, NJ 08854. Phone: (732) 235-5048. Fax: (732) 235-4783. E-mail:
Roth{at}waksman.rutgers.edu.
 |
REFERENCES |
| 1.
|
Arnold, E.,
A. Jacobo-Molina,
R. G. Nanni,
R. L. Williams,
X. Lu,
J. Ding,
J. Arthur,
D. Clark,
A. Zhang,
A. L. Ferris,
P. Clark,
A. Hizi, and S. H. Hughes.
1992.
Structure of HIV-1 reverse transcriptase/DNA complex a 7A resolution showing active site locations.
Nature
357:85-89[CrossRef][Medline].
|
| 2.
|
Arts, E. J., and S. F. L. Grice.
1998.
Interaction of retroviral reverse transcriptase with template-primer duplex during replication.
Prog. Nucleic Acid Res. Mol. Biol.
58:339-393[Medline].
|
| 3.
|
Arts, E. J.,
S. R. Stetor,
S. Li,
J. W. Rausch,
K. J. Howard,
B. Ehresmann,
T. W. North,
B. M. Wohrl,
R. S. Goody,
M. A. Wainberg, and S. F. J. LeGrice.
1996.
Initiation of ( ) strand DNA synthesis from tRNALys,3 on lentiviral RNAs: implications of specific HIV-1 RNA-tRNALys,3 interactions inhibiting primer utilization by retroviral reverse transcriptases.
Proc. Natl. Acad. Sci. USA
93:10063-10068[Abstract/Free Full Text].
|
| 4.
|
Auxilien, S.,
G. Keith,
S. F. J. Le Grice, and J.-L. Darlix.
1999.
Role of post-transcriptional modifications of primer tRNALys,3 in the fidelity and efficacy of plus strand DNA transfer during HIV-1 reverse transcription.
J. Biol. Chem.
274:4412-4420[Abstract/Free Full Text].
|
| 5.
|
Beard, W. A.,
K. Bebenek,
T. A. Darden,
L. Li,
R. Prasad,
T. A. Kunkel, and S. H. Wilson.
1998.
Vertical-scanning mutagenesis of a critical tryptophan in the minor groove binding track of HIV-1 reverse transcriptase.
J. Biol. Chem.
273:30435-30442[Abstract/Free Full Text].
|
| 6.
|
Bebenek, K.,
W. A. Beard,
J. R. Casas-Finet,
H. R. Kim,
T. A. Darden,
S. H. Wilson, and T. A. Kunkel.
1995.
Reduced frameshift fidelity and processivity of HIV-1 reverse transcriptase mutants containing alanine substitutions in helix H of the thumb subdomain.
J. Biol. Chem.
270:19516-19523[Abstract/Free Full Text].
|
| 7.
|
Ben-Artzi, H.,
J. Shemesh,
E. Zeelon,
B. Amit,
L. Kleiman,
M. Gorecki, and A. Panet.
1996.
Molecular analysis of the second template switch during reverse transcription of the HIV RNA template.
Biochemistry
35:10549-10557[CrossRef][Medline].
|
| 8.
|
Blain, S. W., and S. P. Goff.
1995.
Effects on DNA synthesis and translocation caused by mutations in the RNase H domain of Moloney murine leukemia virus reverse transcriptase.
J. Virol.
69:4440-4452[Abstract].
|
| 9.
|
Cameron, C. E.
1997.
Mutations in HIV reverse transcriptase which alter RNase H activity and decrease strand transfer efficiency are suppressed by HIV nucleocapsid protein.
Biochemistry
94:6700-6705.
|
| 10.
|
Cirino, N. M.,
C. E. Cameron,
J. S. Smith,
J. W. Rausch,
M. J. Roth,
S. J. Benkovic, and S. F. J. Le Grice.
1995.
Divalent cation modulation of ribonuclease functions of human immunodeficiency virus reverse transcriptase.
Biochemistry
34:9936-9943[CrossRef][Medline].
|
| 11.
|
Das, K.,
J. Ding,
Y. Hsiou,
A. D. J. Clark,
H. Moereels,
L. Koymans,
K. Andries,
R. Pauwel,
P. A. J. Janssen,
P. L. Boyer,
P. Clark,
R. H. J. Smith,
M. B. K. Smith,
C. J. Michejda,
S. H. Hughes, and E. Arnold.
1996.
Crystal structure of 8-CI and 9-CI TIBO complexed with wild type HIV-1 RT and 8-CI TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
J. Mol. Biol.
264:1085-1100[CrossRef][Medline].
|
| 12.
|
DeStefano, J.
1995.
The orientation of human immunodeficiency virus reverse transcriptase on nucleic acid hybrids.
Nucleic Acids Res.
23:3901-3908[Abstract/Free Full Text].
|
| 13.
|
DeStefano, J. J.,
W. Wu,
J. Seehra,
J. M. Coy,
D. Laston,
E. Albone,
P. J. Fay, and R. A. Bambara.
1994.
Characterization of an RNase H defective mutant of human immunodeficiency virus type 1 reverse transcriptase having an aspartate to asparagine change at position 498.
Biochim. Biophys. Acta
1219:380-388[Medline].
|
| 14.
|
DiMarzoVeronese, F.,
T. D. Copeland,
A. L. D. Vico,
R. Rahman,
S. Oroszlan,
R. C. Gallo, and M. G. Sarngadharan.
1986.
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-II/LAV.
Science
231:1289-1291[Abstract/Free Full Text].
|
| 15.
|
Ding, J.,
K. Das,
H. Moerells,
L. Koymans,
K. Andries,
P. A. Janseen,
S. H. Hughes, and E. Arnold.
1995.
Structure of HIV-1 RT/TIBO R86183 reveals similarity in the binding of diverse nonnucleoside inhibitors.
Nat. Struct. Biol.
2:407-415[CrossRef][Medline].
|
| 16.
|
Ding, J.,
K. Das,
C. Tantillo,
W. Zhang,
A. D. Clark,
S. Jessen Jr,
X. Lu,
Y. Hsiou,
A. Jacobo-Molina,
K. Andries,
R. Pawels,
H. Moereels,
L. Koymans,
P. A. J. Janssen, and R. H. Smith, Jr.
1995.
Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibitor -APA R95845 at 2.8A resolution.
Structure
3:365-379[Medline].
|
| 17.
|
Dudding, L. R.,
N. C. Nkabinde, and V. Mizrahi.
1991.
Analysis of the RNA- and DNA-dependent DNA polymerase activities of point mutants of HIV-1 reverse transcriptase lacking ribonuclease H activity.
Biochemistry
30:10498-10506[CrossRef][Medline].
|
| 18.
|
Fan, N.,
K. B. Rank,
D. E. Slade,
S. M. Poppe,
D. B. Evans,
L. A. Kopta,
R. A. Olmsted,
R. C. Thomas,
W. G. Tarpley, and S. K. Sharma.
1996.
A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.
Biochemistry
35:9737-9745[CrossRef][Medline].
|
| 19.
|
Fassati, A., and S. P. Goff.
1999.
Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus.
J. Virol.
73:8919-8925[Abstract/Free Full Text].
|
| 20.
|
Furfine, E. S., and J. E. Reardon.
1991.
Reverse transcriptase-RNase H from the human immunodeficiency virus.
J. Biol. Chem.
266:406-412[Abstract/Free Full Text].
|
| 21.
|
Gao, H.-Q.,
P. L. Boyer,
E. Arnold, and S. H. Hughes.
1998.
Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase.
J. Mol. Biol.
277:559-572[CrossRef][Medline].
|
| 22.
|
Gao, H.-Q.,
S. G. Sarfianos,
E. Arnold, and S. H. Hughes.
1999.
Similarities and differences in the RNase H activities of human immunodeficiency virus type 1 reverse transcriptase and Moloney murine leukemia virus reverse transcriptase.
J. Mol. Biol.
294:1097-1113[CrossRef][Medline].
|
| 23.
|
Ghosh, M.,
K. J. Howard,
C. E. Cameron,
S. J. Benkovic,
S. H. Hughes, and S. F. J. LeGrice.
1995.
Truncating alpha-helix E' of p66 human immunodeficiency virus reverse transcriptase modulates RNase H function and impairs DNA strand transfer.
J. Biol. Chem.
270:7058-7976.
|
| 24.
|
Huang, H.,
R. Chopra,
G. L. Verdine, and S. C. Harrison.
1998.
Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.
Science
282:1669-1675[Abstract/Free Full Text].
|
| 25.
|
Isel, C.,
J. M. Lanchy,
S. F. L. Grice,
C. Ehresmann,
B. Ehresmann, and R. Marquet.
1996.
Specific initiation and switch to elongation of human immunodeficiency virus type 1 reverse transcription require the post-transcriptional modifications of primer tRNA3Lys.
EMBO J. 1996.
15:917-924[Medline].
|
| 26.
|
Isel, C.,
R. Marquet,
G. Keith,
C. Ehresmann, and B. Ehresmann.
1993.
Modified nucleotides of tRNA(3Lys) modulate primer/template loop-loop interaction in the initiation complex of HIV-1 reverse transcription.
J. Biol. Chem.
268:25269-25272[Abstract/Free Full Text].
|
| 27.
|
Isel, C.,
E. Westhof,
C. Massire,
S. F. Le Grice,
B. Ehresmann,
C. Ehresmann, and R. Marquet.
1999.
Structural basis for the specificity of the initiation of HIV-1 reverse transcription.
EMBO J.
18:1038-1048[CrossRef][Medline].
|
| 28.
|
Jiang, M.,
J. Mak,
A. Lahda,
E. Cohen,
M. Klein,
B. Rovinski, and L. Kleiman.
1993.
Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1.
J. Virol.
67:3246-3253[Abstract/Free Full Text].
|
| 29.
|
Jones, J. S.,
R. A. Allan, and H. M. Temin.
1994.
One viral RNA is sufficient for synthesis of viral DNA.
J. Virol.
68:207-216[Abstract/Free Full Text].
|
| 30.
|
Kohlstaedt, L. A.,
J. Wang,
J. M. Friedman,
P. A. Rice, and T. A. Steitz.
1992.
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.
Science
256:1783-1790[Abstract/Free Full Text].
|
| 31.
|
Lanchy, J.,
G. Keith,
S. F. J. Le Grice,
B. Ehresmann,
C. Ehresmann, and R. Marquet.
1998.
Contacts between reverse transcriptase and the primer strand govern the transition from initiation to elongation of HIV-1 reverse transcription.
J. Biol. Chem.
273:24425-24432[Abstract/Free Full Text].
|
| 32.
|
Le Grice, S. F. J., and F. Gruninger-Leitch.
1990.
Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography.
Eur. J. Biol.
187:307.
|
| 33.
|
Li, X.,
J. Mak,
E. J. Arts,
Z. Gu,
L. Kleiman,
M. A. Wainberg, and M. A. Parniak.
1994.
Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication.
J. Virol.
68:6198-6206[Abstract/Free Full Text].
|
| 34.
|
Lightfoot, M. M.,
J. E. Coligan,
T. M. Folks,
A. S. Fauci,
M. A. Martin, and S. Venkatesan.
1986.
Structural characterization of reverse transcriptase and endonuclease polypeptides of acquired immunodeficiency syndrome virus.
J. Virol.
60:771-775[Abstract/Free Full Text].
|
| 35.
|
Mak, J.,
M. Jiang,
M. A. Wainberg,
M.-L. Hammarskjold,
D. Rekosh, and I. Kleiman.
1994.
Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles.
J. Virol.
68:2065-2072[Abstract/Free Full Text].
|
| 36.
|
Mak, J.,
A. Khorchid,
Q. Cao,
Y. Huang,
I. Lowy,
M. A. Parniak,
V. R. Prasad,
M. A. Wainberg, and L. Kleiman.
1997.
Effects of mutations in Pr160 gag-pol upon tRNA(Lys3) and Pr160 gag-pol incorporation into HIV-1.
J. Mol. Biol.
265:4555-4564.
|
| 37.
|
Mizrahi, V.,
G. M. Lazarus,
L. M. Miles,
C. A. Meyers, and C. DeBouck.
1989.
Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities.
Arch. Biochem. Biophys.
273:347-358[CrossRef][Medline].
|
| 38.
|
Nicholls, A.,
K. A. Sharp, and B. Honig.
1991.
Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.
Proteins
11:281-296[CrossRef][Medline].
|
| 39.
|
Palaniappan, C.,
G. M. Fuentes,
L. Rodriguez-Rodriguez,
P. J. Fay, and R. A. Bambara.
1996.
Helix structure and ends of RNA/DNA hybrids direct the cleavage specificity of HIV-1 reverse transcriptase RNase H.
J. Biol. Chem.
271:2063-2070[Abstract/Free Full Text].
|
| 40.
|
Palaniappan, C.,
J. K. Kim,
M. Wisniewski,
P. J. Fay, and R. A. Bambara.
1998.
Control of initiation of viral plus strand DNA synthesis by HIV reverse transcriptase.
J. Biol. Chem.
273:3808-3816[Abstract/Free Full Text].
|
| 41.
|
Parthasarathi, S.,
A. Varela-Echavarria,
Y. Ron,
B. D. Preston, and J. P. Dougherty.
1995.
Genetic rearrangements occurring during a single cycle of murine leukemia virus vector replication: characterization and implications.
J. Virol.
69:7991-8000[Abstract].
|
| 42.
|
Peliska, J. A., and S. J. Benkovic.
1992.
Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase.
Science
258:1112-1118[Abstract/Free Full Text].
|
| 43.
|
Powell, M. D.,
W. A. Beard,
K. Bebenek,
K. J. Howard,
S. F. J. Le Grice,
T. A. Darden,
T. A. Kunkel,
S. H. Wilson, and J. G. Levin.
1999.
Residues in the H and I helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer.
J. Biol. Chem.
274:19885-19893[Abstract/Free Full Text].
|
| 44.
|
Powell, M. D.,
M. Ghosh,
P. S. Jacques,
K. J. Howard,
S. F. L. Grice, and J. G. Levin.
1997.
Alanine-scanning mutations in the "primer grip" of p66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity.
J. Biol. Chem.
272:13262-13269[Abstract/Free Full Text].
|
| 45.
|
Ren, J.,
R. Esnouf,
E. Garman,
D. Somers,
C. Ross,
I. Kiraby,
J. Keeling,
G. Darby,
Y. Jones,
D. Stuart, and D. Stammers.
1995.
High resolution structures of HIV-1 RT from four RT-inhibitor complexes.
Nat. Struct. Biol.
2:293-308[CrossRef][Medline].
|
| 46.
|
Roth, M. J.,
P. Schwartzberg, and S. P. Goff.
1989.
Structure of the termini of DNA intermediates in the integration of retroviral DNA: dependence of IN function and terminal DNA sequence.
Cell
58:47-54[CrossRef][Medline].
|
| 47.
|
Schatz, O.,
F. V. Cromme,
F. Gruninger-Leitch, and S. F. J. Le Grice.
1989.
Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNase H function.
FEBS Lett.
237:311-314.
|
| 48.
|
Smith, C. M.,
W. B. Potts III,
J. S. Smith, and M. J. Roth.
1997.
RNase H cleavage of tRNAPro mediated by M-MuLV and HIV-1 reverse transcriptases.
Virology
229:437-446[CrossRef][Medline].
|
| 49.
|
Smith, C. M.,
O. Leon,
J. S. Smith, and M. J. Roth.
1998.
Sequence requirements for removal of tRNA by an isolated HIV-1 RNase H domain.
J. Virol.
72:6805-6812[Abstract/Free Full Text].
|
| 50.
|
Smith, C. M.,
J. S. Smith, and M. J. Roth.
1999.
RNase H requirements for the second strand transfer reaction of HIV-1 reverse transcription.
J. Virol.
73:6573-6581[Abstract/Free Full Text].
|
| 51.
|
Smith, J. S.,
S. Kim, and M. J. Roth.
1990.
Analysis of long terminal repeat circle junctions of human immunodeficiency virus type 1.
J. Virol.
64:6286-6290[Abstract/Free Full Text].
|
| 52.
|
Smith, J. S., and M. J. Roth.
1993.
Purification and characterization of an active human immunodeficiency virus type 1 RNase H domain.
J. Virol.
67:4037-4049[Abstract/Free Full Text].
|
| 53.
|
Smith, J. S., and M. J. Roth.
1992.
Specificity of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H in removal of the minus-strand primer, tRNALys3.
J. Biol. Chem.
267:15071-15079[Abstract/Free Full Text].
|
| 54.
|
Wakefield, J. K., and C. D. Morrow.
1996.
Mutations within the primer binding site of the human immunodeficiency virus type 1 define sequence requirements essential for reverse transcription.
Virology
220:290-298[CrossRef][Medline].
|
| 55.
|
Wohrl, B. M.,
B. Ehresmann,
G. Keith, and S. F. Le Grice.
1993.
Nuclease footprinting of human immunodeficiency virus/tRNA(Lys-3) complex.
J. Biol. Chem.
268:13617-13624[Abstract/Free Full Text].
|
| 56.
|
Wohrl, B. M.,
M. M. Georgiadis,
A. Telesnitsky,
W. A. Hendrickson, and S. F. Le Grice.
1995.
Footprint analysis of replicating murine leukemia virus reverse transcriptase.
Science
267:96-99[Abstract/Free Full Text].
|
| 57.
|
Wohrl, B. M.,
C. Tantillo,
E. Arnold, and S. F. Le Grice.
1995.
An expanded model of replicating human immunodeficiency virus reverse transcriptase.
Biochemistry
34:5343-5356[CrossRef][Medline].
|
| 58.
|
Wu, T.,
J. Guo,
J. Bess,
L. E. Henderson, and J. G. Levin.
1999.
Molecular requirements for human immunodeficiency virus type 1 plus-strand transfer: analysis in reconstituted and endogenous reverse transcription systems.
J. Virol.
73:4794-4805[Abstract/Free Full Text].
|
| 59.
|
Zhan, X., and R. J. Crouch.
1997.
The isolated RNase H domain of murine leukemia virus reverse transcriptase. Retention of activity with concomitant loss of specificity.
J. Biol. Chem.
272:22023-22029[Abstract/Free Full Text].
|
| 60.
|
Zhan, Z.,
C.-K. Tan,
W. A. Scott,
A. M. Mian,
K. M. Downey, and A. G. So.
1994.
Catalytically distinct conformations of the ribonuclease H of HIV-1 reverse transcriptase by substrate cleavage patterns and inhibition by azidothymidylate and N-ethylmaleimide.
Biochemistry
33:1366-1372[CrossRef][Medline].
|
Journal of Virology, October 2000, p. 9668-9679, Vol. 74, No. 20
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zuniga, R., Sengupta, S., Snyder, C., Leon, O., Roth, M. J.
(2004). Expression of the C-terminus of HIV-1 reverse transcriptase p66 and p51 subunits as a single polypeptide with RNase H activity. Protein Eng Des Sel
17: 581-587
[Abstract]
[Full Text]